ATE352309T1 - Plasmaglucosylceramiddefizienz als risikofaktor für thrombose und modulator von anticoagulant protein c - Google Patents

Plasmaglucosylceramiddefizienz als risikofaktor für thrombose und modulator von anticoagulant protein c

Info

Publication number
ATE352309T1
ATE352309T1 AT02760992T AT02760992T ATE352309T1 AT E352309 T1 ATE352309 T1 AT E352309T1 AT 02760992 T AT02760992 T AT 02760992T AT 02760992 T AT02760992 T AT 02760992T AT E352309 T1 ATE352309 T1 AT E352309T1
Authority
AT
Austria
Prior art keywords
glccer
protein
thrombosis
gb3cer
methods
Prior art date
Application number
AT02760992T
Other languages
English (en)
Inventor
John H Griffin
Hiroshi Deguchi
Jose Fernandez
Original Assignee
John H Griffin
Hiroshi Deguchi
Jose Fernandez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by John H Griffin, Hiroshi Deguchi, Jose Fernandez filed Critical John H Griffin
Application granted granted Critical
Publication of ATE352309T1 publication Critical patent/ATE352309T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT02760992T 2001-02-28 2002-02-28 Plasmaglucosylceramiddefizienz als risikofaktor für thrombose und modulator von anticoagulant protein c ATE352309T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27210301P 2001-02-28 2001-02-28
US27804501P 2001-03-22 2001-03-22

Publications (1)

Publication Number Publication Date
ATE352309T1 true ATE352309T1 (de) 2007-02-15

Family

ID=26955302

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02760992T ATE352309T1 (de) 2001-02-28 2002-02-28 Plasmaglucosylceramiddefizienz als risikofaktor für thrombose und modulator von anticoagulant protein c

Country Status (6)

Country Link
US (2) US6756208B2 (de)
EP (1) EP1370570B1 (de)
AT (1) ATE352309T1 (de)
AU (1) AU2002326291A1 (de)
DE (1) DE60217835D1 (de)
WO (1) WO2002102325A2 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
HUP0501111A2 (en) 2001-10-15 2007-12-28 Chiron Corp Treatment of severe pneumonia by administration of tissue factor pathway inhibitor
DE10206938A1 (de) * 2002-02-19 2003-09-04 Oce Printing Systems Gmbh Verfahren und Einrichtung zum Drucken, wobei eine hydrophile Schicht erzeugt und diese strukturiert wird
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
WO2005032462A2 (en) 2003-02-27 2005-04-14 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
US20040171522A1 (en) * 2003-02-27 2004-09-02 Yaron Ilan Regulation of immune responses by manipulation of intermediary metabolite levels
US20070184058A1 (en) * 2003-02-27 2007-08-09 Yaron Ilan Glucocerebroside treatment of pulmonary or respiratory diseases or disorders
US9717754B2 (en) 2003-02-27 2017-08-01 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
AU2005244249A1 (en) * 2004-03-17 2005-11-24 Novartis Vaccines And Diagnostics, Inc. Treatment of severe community-acquired pneumonia by admistration of tissue factor pathway inhibitor (TFPI)
EP1773371A4 (de) * 2004-07-23 2009-12-30 Univ Rochester Aktiviertes protein c hemmt unerwünschte effekte von plasminogenaktivator im gehirn
US20090068207A1 (en) * 2005-04-15 2009-03-12 Vascular Biogenics Ltd. Compositions Containing Beta 2-Glycoprotein I-Derived Peptides for the Prevention and/or Treatment of Vascular Disease
KR20090004926A (ko) 2006-03-09 2009-01-12 올테크 어소시에이츠, 인크. 복합 관형 부재, 관형 부재, 드리프트 튜브, 카트리지/임팩터 조립체, 카트리지, 전자 회로, 증기화 광 산란 검출기, 테스트 샘플 분석 방법 및 입력된 전압 신호 처리 방법
US20080194527A1 (en) * 2007-02-14 2008-08-14 Tcp Innovations Ltd Compositions and combinations 2
US20090286740A1 (en) * 2008-05-15 2009-11-19 Fibrex Medical Research & Development Gmbh Peptides and derivatives thereof, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
US20120148547A1 (en) * 2009-09-01 2012-06-14 Hadasit Medical Reasearch Services & Development Ltd. Combination of vitamin e and beta-glycosphingolipids in compositions and methods for preventing and treating hepatic disorders
CA2781277C (en) 2009-11-17 2018-01-09 Baylor Research Institute Urinary triaosylceramide (gb3) as a marker of cardiac disease
US20110136858A1 (en) * 2009-12-04 2011-06-09 Grainger David J Preferred Combination Therapy
CA2787318A1 (en) * 2010-01-21 2011-07-28 Paul Bradley Addis Composition for perinatal and neonatal stroke
US20120178105A1 (en) * 2011-01-10 2012-07-12 Genzyme Corporation Detection of globotriaosylceramide (glc) in human urine samples using an antibody sandwich
CN102798598A (zh) * 2011-05-25 2012-11-28 兆科药业（合肥）有限公司 一种检测磷脂依赖性凝血因子x激活物酶活性的方法
LT2782584T (lt) 2011-11-23 2021-09-10 Therapeuticsmd, Inc. Natūralios kombinuotos pakaitinės hormonų terapijos kompozicijos ir gydymas
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CN104122396A (zh) * 2013-04-23 2014-10-29 中国科学院上海生命科学研究院 维生素k依赖性蛋白s作为糖尿病标志物的应用
CN103308636B (zh) * 2013-04-28 2014-04-09 山东信立泰药业有限公司 一种D-(+)-α-(2-噻吩乙胺基)-α-(2-氯苯基)乙酸甲酯或其盐的质量控制方法及其在氯吡格雷生产中的应用
US20170035791A1 (en) * 2014-04-14 2017-02-09 Natural Shield Israel 2016 Ltd Combination of beta-glucosylceramide and polyethoxylated castor oil and other adjuvants for controling blood sugar levels, immunoprotection and hepatoprotection
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US11058750B2 (en) * 2015-12-03 2021-07-13 Mor Research Applications Ltd. Compositions and methods for treatment of ocular diseases
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US11505556B2 (en) * 2017-12-12 2022-11-22 Xalud Therapeutics, Inc. Halogenated derivatives of morphinans and uses thereof
CN108931595B (zh) * 2018-06-20 2021-05-11 广东省测试分析研究所（中国广州分析测试中心） 一种明胶型凝胶糖果中磷脂酰丝氨酸含量的测定方法
CN108836897A (zh) * 2018-08-21 2018-11-20 湖南博隽生物医药有限公司 一种含有玫瑰精油的化妆品及其制备方法
EP3632427A1 (de) * 2018-10-01 2020-04-08 Mehdi Namdar Neue mittel zur verwendung bei der behandlung von herzrhythmusstörungen
CN109700998B (zh) * 2019-02-25 2022-02-08 曾湘红 一种复方肌肤损伤再生修复剂及其制备方法
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
CN112375133A (zh) * 2020-09-18 2021-02-19 江苏艾迪药业股份有限公司 亲和层析柱纯化凝血酶调节蛋白的方法
CN113243338A (zh) * 2021-05-14 2021-08-13 福州大学 一种小鼠缺血性卒中模型的构建与评估方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4416872A (en) * 1982-03-17 1983-11-22 The United States Of America As Represented By The Secretary Of The Army Treatment of malaria with liposomes containing 8-aminoquinoline derivatives and glycoconjugates
US4766111A (en) * 1985-10-31 1988-08-23 Trustees Of Boston University Lipids with plasmin inhibitory properties
US5047354A (en) * 1987-10-30 1991-09-10 Foegh Marie L Thromboxane B2 assay for coronary artery thrombosis
JPH02270823A (ja) * 1989-04-11 1990-11-05 Ube Nitto Kasei Co Ltd 抗血液凝固剤
DE4025330A1 (de) * 1990-08-09 1992-02-13 Basf Ag Lipidderivate und verfahren zu deren herstellung
FR2764511B1 (fr) 1997-06-13 2000-09-08 Sanofi Sa Compositions pour le traitement et la prevention de la thrombose arterielle et utilisation d'un inhibiteur du facteur xa seul et/ou en combinaison avec un antiagregant plaquettaire
CA2316041A1 (en) * 1997-12-30 1999-07-08 Pam Fredman Galactosylceramide, glucosylceramide, lactosylceramide, and specific catchers therefor for use in the prophylaxis or therapy of prediabetes, diabetes and/or associated complications
AU756008B2 (en) * 1998-07-27 2003-01-02 Johns Hopkins University, The Methods for treating conditions modulated by lactosylceramide
EP1161279A1 (de) * 1999-03-11 2001-12-12 Du Pont Pharmaceuticals Company Behandlung von thrombose mit kombinationen aus factor xa hemmern mit aspirin, gewebe-plasminogenaktivatoren (tpa), gpiib/iiia antagonisten, niedermolekulare heparin oder heparin

Also Published As

Publication number Publication date
AU2002326291A1 (en) 2003-01-02
US20020177563A1 (en) 2002-11-28
WO2002102325A3 (en) 2003-09-12
DE60217835D1 (en) 2007-03-15
EP1370570B1 (de) 2007-01-24
EP1370570A4 (de) 2004-10-13
EP1370570A2 (de) 2003-12-17
WO2002102325A2 (en) 2002-12-27
US6756208B2 (en) 2004-06-29
US20040132688A1 (en) 2004-07-08

Similar Documents

Publication Publication Date Title
ATE352309T1 (de) Plasmaglucosylceramiddefizienz als risikofaktor für thrombose und modulator von anticoagulant protein c
Heeb et al. Protein S binds to and inhibits factor Xa.
Koppelman et al. Inhibition of the intrinsic factor X activating complex by protein S: evidence for a specific binding of protein S to factor VIII
Wood et al. Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation
Greengard et al. Binding of coagulation factor XI to washed human platelets
Schwarz et al. Identification and quantitation of protein S in human platelets
Huntington Molecular recognition mechanisms of thrombin
Giles et al. The coagulant-active phospholipid content is a major determinant of in vivo thrombogenicity of prothrombin complex (factor IX) concentrates in rabbits
Friedman et al. A spectrum of partially carboxylated prothrombins in the plasmas of coumarin-treated patients
Baglia et al. Prothrombin is a cofactor for the binding of factor XI to the platelet surface and for platelet-mediated factor XI activation by thrombin
van ‘t Veer et al. An in vitro analysis of the combination of hemophilia A and factor VLEIDEN
Okajima et al. Effect of protein C and activated protein C on coagulation and fibrinolysis in normal human subjects
Ahnström et al. Activated protein C cofactor function of protein S: a novel role for a γ-carboxyglutamic acid residue
De Cristofaro et al. Structural and functional mapping of the thrombin domain involved in the binding to the platelet glycoprotein Ib
Gray et al. Recombinant factor VIIa analog NN1731 (V158D/E296V/M298Q-FVIIa) enhances fibrin formation, structure and stability in lipidated hemophilic plasma
Zhang et al. Nitrophorin-2: a novel mixed-type reversible specific inhibitor of the intrinsic factor-X activating complex
Mumford et al. A Tyr346→ Cys substitution in the interdomain acidic region a1 of factor VIII in an individual with factor VIII: C assay discrepancy
George et al. Correction of human hemophilia A whole blood abnormalities with a novel bypass agent: zymogen‐like FXaI16L
Brophy et al. Use of global assays to monitor emicizumab prophylactic therapy in patients with haemophilia A with inhibitors.
Saba et al. Hemostasis and thrombosis: Practical guidelines in clinical management
Wu et al. Role of procoagulant lipids in human prothrombin activation. 1. Prothrombin activation by factor Xa in the absence of factor Va and in the absence and presence of membranes
Butenas et al. Decryption of tissue factor
Lu et al. Ile73Asn mutation in protein C introduces a new N-linked glycosylation site on the first EGF-domain of protein C and causes thrombosis
Barrow et al. Inhibition by heparin of thrombin-catalyzed activation of the factor VIII-von Willebrand factor complex.
Booyse et al. Normal but not hypertriglyceridemic very low-density lipoprotein induces rapid release of tissue plasminogen activator from cultured human umbilical vein endothelial cells

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties